Cytoreduction and Intraperitoneal Chemotherapy for the Management of Non-Gynecological Peritoneal Surface Malignancy

T. D. Yan, J. Esquivel, P. Carmignani, P. H. Sugarbaker

Research output: Contribution to journalArticle

Abstract

Peritoneal surface malignancy can arise from pseudomyxoma peritonei, gastrointestinal carcinoma, abdomino-pelvic sarcoma and peritoneal mesothelioma. In the past, only palliative treatments were offered and the results were poor. We have proposed a new concept in managing patients with peritoneal surface malignancy. It involves an aggressive combined treatment modality of cytoreduction and perioperative intraperitoneal chemotherapy. The results are promising for patients with pseudomyxoma peritonei, peritoneal mesothelioma and well-selected patients with invasive peritoneal surface malignancies. The success in such comprehensive treatment depends on tumor biology, patient's co-morbidities, the completeness of cytoreduction, the efficacy of intraperitoneal chemotherapy administration and the surgeon's experience. The importance of patient selection is emphasized. The rationales and the outline of the current management strategies are described. Large phase II studies have demonstrated the marked survival advantage in this aggressive approach to peritoneal surface malignancy.

Original languageEnglish (US)
Pages (from-to)109-117
Number of pages9
JournalJournal of Experimental and Clinical Cancer Research
Volume22
Issue number4 SUPPL.
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Drug Therapy
Pseudomyxoma Peritonei
Mesothelioma
Neoplasms
Palliative Care
Sarcoma
Patient Selection
Morbidity
Carcinoma
Survival
Therapeutics

Keywords

  • Carcinomatosis
  • Intraperitoneal chemotherapy
  • Peritoneal mesothelioma
  • Peritonectomy
  • Sarcomatosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cytoreduction and Intraperitoneal Chemotherapy for the Management of Non-Gynecological Peritoneal Surface Malignancy. / Yan, T. D.; Esquivel, J.; Carmignani, P.; Sugarbaker, P. H.

In: Journal of Experimental and Clinical Cancer Research, Vol. 22, No. 4 SUPPL., 12.2003, p. 109-117.

Research output: Contribution to journalArticle

Yan, T. D. ; Esquivel, J. ; Carmignani, P. ; Sugarbaker, P. H. / Cytoreduction and Intraperitoneal Chemotherapy for the Management of Non-Gynecological Peritoneal Surface Malignancy. In: Journal of Experimental and Clinical Cancer Research. 2003 ; Vol. 22, No. 4 SUPPL. pp. 109-117.
@article{ac8682e610ce493b8ec36fcc0c25365d,
title = "Cytoreduction and Intraperitoneal Chemotherapy for the Management of Non-Gynecological Peritoneal Surface Malignancy",
abstract = "Peritoneal surface malignancy can arise from pseudomyxoma peritonei, gastrointestinal carcinoma, abdomino-pelvic sarcoma and peritoneal mesothelioma. In the past, only palliative treatments were offered and the results were poor. We have proposed a new concept in managing patients with peritoneal surface malignancy. It involves an aggressive combined treatment modality of cytoreduction and perioperative intraperitoneal chemotherapy. The results are promising for patients with pseudomyxoma peritonei, peritoneal mesothelioma and well-selected patients with invasive peritoneal surface malignancies. The success in such comprehensive treatment depends on tumor biology, patient's co-morbidities, the completeness of cytoreduction, the efficacy of intraperitoneal chemotherapy administration and the surgeon's experience. The importance of patient selection is emphasized. The rationales and the outline of the current management strategies are described. Large phase II studies have demonstrated the marked survival advantage in this aggressive approach to peritoneal surface malignancy.",
keywords = "Carcinomatosis, Intraperitoneal chemotherapy, Peritoneal mesothelioma, Peritonectomy, Sarcomatosis",
author = "Yan, {T. D.} and J. Esquivel and P. Carmignani and Sugarbaker, {P. H.}",
year = "2003",
month = "12",
language = "English (US)",
volume = "22",
pages = "109--117",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Cytoreduction and Intraperitoneal Chemotherapy for the Management of Non-Gynecological Peritoneal Surface Malignancy

AU - Yan, T. D.

AU - Esquivel, J.

AU - Carmignani, P.

AU - Sugarbaker, P. H.

PY - 2003/12

Y1 - 2003/12

N2 - Peritoneal surface malignancy can arise from pseudomyxoma peritonei, gastrointestinal carcinoma, abdomino-pelvic sarcoma and peritoneal mesothelioma. In the past, only palliative treatments were offered and the results were poor. We have proposed a new concept in managing patients with peritoneal surface malignancy. It involves an aggressive combined treatment modality of cytoreduction and perioperative intraperitoneal chemotherapy. The results are promising for patients with pseudomyxoma peritonei, peritoneal mesothelioma and well-selected patients with invasive peritoneal surface malignancies. The success in such comprehensive treatment depends on tumor biology, patient's co-morbidities, the completeness of cytoreduction, the efficacy of intraperitoneal chemotherapy administration and the surgeon's experience. The importance of patient selection is emphasized. The rationales and the outline of the current management strategies are described. Large phase II studies have demonstrated the marked survival advantage in this aggressive approach to peritoneal surface malignancy.

AB - Peritoneal surface malignancy can arise from pseudomyxoma peritonei, gastrointestinal carcinoma, abdomino-pelvic sarcoma and peritoneal mesothelioma. In the past, only palliative treatments were offered and the results were poor. We have proposed a new concept in managing patients with peritoneal surface malignancy. It involves an aggressive combined treatment modality of cytoreduction and perioperative intraperitoneal chemotherapy. The results are promising for patients with pseudomyxoma peritonei, peritoneal mesothelioma and well-selected patients with invasive peritoneal surface malignancies. The success in such comprehensive treatment depends on tumor biology, patient's co-morbidities, the completeness of cytoreduction, the efficacy of intraperitoneal chemotherapy administration and the surgeon's experience. The importance of patient selection is emphasized. The rationales and the outline of the current management strategies are described. Large phase II studies have demonstrated the marked survival advantage in this aggressive approach to peritoneal surface malignancy.

KW - Carcinomatosis

KW - Intraperitoneal chemotherapy

KW - Peritoneal mesothelioma

KW - Peritonectomy

KW - Sarcomatosis

UR - http://www.scopus.com/inward/record.url?scp=1842426246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842426246&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 109

EP - 117

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 4 SUPPL.

ER -